The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
Gilles A. Salles
Research Funding - Gilead Sciences
Thomas J. Ervin
Research Funding - Gilead Sciences
Robert Dichmann
Research Funding - Gilead Sciences
Rod Ramchandren
Research Funding - Gilead Sciences
Ray D. Page
Research Funding - Gilead Sciences
Ramakrishna Battini
Research Funding - Gilead Sciences
William E. Lawler
Research Funding - Gilead Sciences
Leanne Holes
Employment or Leadership Position - Gilead Sciences
Adeboye H. Adewoye
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Sven De Vos
Research Funding - Gilead Sciences